US FDA Dives Back Into Opioid Reviews Under New Division Leadership
Executive Summary
Four new pain drug formulations are heading to advisory committees in January. The meetings will also feature new FDA leadership in the pain/addiction review division following the retirement of Sharon Hertz.
You may also be interested in...
Opioid 'Data Warehouse' Is Part Of US FDA's New Controlled Substances Program
CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.
Long Hot Summer For Novel Drug Reviews Forecast At US FDA
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Esteve’s Tramadol/Celecoxib: US FDA Cites No Major Concerns, But Also No Advantages
Agency’s briefing document for 15 January review of the fixed-dose product combining an opioid and nonsteroidal anti-inflammatory reflects application of opioid benefit/risk framework described in June draft guidance.